These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8600463)

  • 1. Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells.
    Ohta Y; Kijima H; Ohkawa T; Kashani-Sabet M; Scanlon KJ
    Nucleic Acids Res; 1996 Mar; 24(5):938-42. PubMed ID: 8600463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes.
    Ohta Y; Kijima H; Kashani-Sabet M; Scanlon KJ
    J Invest Dermatol; 1996 Feb; 106(2):275-80. PubMed ID: 8601728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribozyme as an approach for growth suppression of human pancreatic cancer.
    Kijima H; Scanlon KJ
    Mol Biotechnol; 2000 Jan; 14(1):59-72. PubMed ID: 10911615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer.
    Li M; Lonial H; Citarella R; Lindh D; Colina L; Kramer R
    Cancer Gene Ther; 1996; 3(4):221-9. PubMed ID: 8853546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H-ras ribozyme-mediated alteration of the human melanoma phenotype.
    Ohta Y; Tone T; Shitara T; Funato T; Jiao L; Kashfian BI; Yoshida E; Horng M; Tsai P; Lauterbach K
    Ann N Y Acad Sci; 1994 May; 716():242-53; discussion 253-6. PubMed ID: 8024198
    [No Abstract]   [Full Text] [Related]  

  • 6. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme.
    Kashani-Sabet M; Funato T; Florenes VA; Fodstad O; Scanlon KJ
    Cancer Res; 1994 Feb; 54(4):900-2. PubMed ID: 8313379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An anti-K-ras ribozyme suppresses oncogene expression and cell growth of human pancreatic cancer.
    Sakuma T; Kijima H; Nishi M; Abe Y; Yamazaki H; Mine T; Nakamura M; Ueyama Y
    Tokai J Exp Clin Med; 2004 Jun; 29(2):35-42. PubMed ID: 15473338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme.
    Funato T; Shitara T; Tone T; Jiao L; Kashani-Sabet M; Scanlon KJ
    Biochem Pharmacol; 1994 Oct; 48(7):1471-5. PubMed ID: 7945447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme.
    Feng M; Cabrera G; Deshane J; Scanlon KJ; Curiel DT
    Cancer Res; 1995 May; 55(10):2024-8. PubMed ID: 7743496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of the malignant phenotype by an anti-ras ribozyme.
    Kashani-Sabet M; Funato T; Tone T; Jiao L; Wang W; Yoshida E; Kashfinn BI; Shitara T; Wu AM; Moreno JG
    Antisense Res Dev; 1992; 2(1):3-15. PubMed ID: 1422085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective reversal of a transformed phenotype by retrovirus-mediated transfer of a ribozyme directed against mutant N-ras.
    Scherr M; Maurer AB; Klein S; Ganser A; Engels JW; Grez M
    Gene Ther; 1998 Sep; 5(9):1227-34. PubMed ID: 9930324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ribozyme targeted the point-mutation of activated oncogene inhibits its expression in vivo].
    Liu G; Chen Y; Zhao X; Dong Y; Chen D
    Yi Chuan Xue Bao; 1996; 23(6):477-85. PubMed ID: 9084224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells.
    Zhang YA; Nemunaitis J; Tong AW
    Mol Biotechnol; 2000 May; 15(1):39-49. PubMed ID: 10911621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of a high activity c-erbB-2 ribozyme using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein.
    Wiechen K; Zimmer C; Dietel M
    Cancer Gene Ther; 1998; 5(1):45-51. PubMed ID: 9476966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture.
    Giannini CD; Roth WK; Piiper A; Zeuzem S
    Nucleic Acids Res; 1999 Jul; 27(13):2737-44. PubMed ID: 10373591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer.
    Irie A; Anderegg B; Kashani-Sabet M; Ohkawa T; Suzuki T; Halks-Miller M; Curiel DT; Scanlon KJ
    Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):341-9. PubMed ID: 10463078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells.
    Funato T; Ishii T; Kambe M; Scanlon KJ; Sasaki T
    Cancer Gene Ther; 2000 Mar; 7(3):495-500. PubMed ID: 10766356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line.
    Eastham JA; Ahlering TE
    J Urol; 1996 Sep; 156(3):1186-8. PubMed ID: 8709343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics.
    Kobayashi H; Takemura Y; Miyachi H
    Hum Cell; 2001 Sep; 14(3):172-84. PubMed ID: 11774737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA.
    Halatsch ME; Schmidt U; Bötefür IC; Holland JF; Ohnuma T
    J Neurosurg; 2000 Feb; 92(2):297-305. PubMed ID: 10659018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.